PDF, Chinese PDF, English SAN MATEO, Calif., and SHANGHAI, China, January 17th, 2019 – Terns Pharmaceuticals Inc., a global biopharmaceutical company focused on discovering and developing molecularly targeted, oral, small-molecule drugs to treat NASH and cancer, announced today the appointment of Erin Quirk, M.D. as Chief Medical Officer (CMO). Dr. Quirk brings more than two […]
Author Archive for: admin
This author has yet to write their bio.Meanwhile lets just say that we are proud admin contributed a whooping 4 entries.
Entries by admin
Download PDF Terns Pharmaceuticals Completes $80 Million Series B Financing to Advance Pipeline of Drugs to Treat NASH and Cancer Proceeds to Support Development of Clinical and Preclinical NASH Candidates Financing Led by Vivo Capital and OrbiMed, joined by Decheng Capital Lilly Asia Ventures, the Series A investor, also investing in the Series B round […]
Download PDF SAN MATEO, CA, and Shanghai, China, April 12, 2018 – Terns Pharmaceuticals Inc., a global biopharmaceutical company focused on discovering and developing molecularly-targeted, oral, small molecule drugs to treat liver disease and cancer, announced today the addition of Juan Carlos Lopez-Talavera, M.D., Ph.D. and Chuan (Joe) Shih, Ph.D. as scientific advisors. “As we […]
Download PDF Deal Includes an FXR Agonist, an SSAO Inhibitor and An Additional Candidate Against a Well-Validated NASH Target Development of Clinical Programs Will Focus on Regulatory Approval in China and Additional Global Markets SAN MATEO, Calif. ‐ Terns Pharmaceuticals Inc., a global biopharmaceutical company focused on discovering and developing molecularly targeted, oral, small molecule drugs […]